William G Kaelin MD

Internal Medicine•Boston, MA

Hematology/Oncology

Professor of Medicine, Harvard Medical School Investigator, Howard Hughes Medical Institute

Join to View Full Profile

44 Binney StreetDana Farber Cancer InstituteBoston, MA 02115
Phone+1 617-632-3975

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1991
Johns Hopkins UniversityResidency, Internal Medicine, 1983 - 1986
Duke University HospitalResidency, Radiology-Diagnostic, 1983 - 1983
Duke University School of MedicineClass of 1982

Certifications & Licensure

MA State Medical License 1987 - 2017

Awards, Honors, & Recognition

Elected Member Institute of Medicine, 2007
Elected Member The American Society for Clinical Investigation, 1997
Investigator Howard Hughes Medical Institute

Publications & Presentations

PubMed

Requirement for Cyclin D1 Underlies Cell Autonomous HIF2-Dependence in Kidney Cancer.
Nitin H Shirole, Devishi Kesar, Yenarae Lee, Amy Goodale, Sudeepa Syamala
Cancer Discovery. 2025-04-04
The INDIGO trial: Precision medicine finally comes to glioma.
Diana D Shi, William G Kaelin
Neuro-Oncology. 2023-11-02
97 citations
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy
Neuro-Oncology. 2023-01-05

Press Mentions

Resveratrol Promotes LRSAM1 E3 Ubiquitin Ligase-Dependent Degradation of Misfolded Proteins Linked with NeurodegenerationSeptember 28th, 2022
Atavistik Bio Announces $60 Million Series a Financing to Advance Genetically-Validated Targets in Metabolic Diseases and CancerAugust 24th, 2021
Dan Hayes Witnessed Cancer History, Now He Is Documenting It in a PodcastJune 4th, 2021
Join now to see all

Grant Support

The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable MutationsDANA-FARBER CANCER INST2016–2030
DF/HCC Kidney Cancer SPOREBETH ISRAEL DEACONESS MEDICAL CENTER2003–2025
DF/HCC Kidney Cancer SPOREBETH ISRAEL DEACONESS MEDICAL CENTER2003–2025
The Rbp2/Jarid1a/Kdm5a Histone Demethylase As A Potential Drug Target In CancerNational Cancer Institute2011–2012
The Von Hippel-Lindau Tumor Suppressor Protein:Roles In Cancer And Oxygen SensingNational Cancer Institute2011
Molecular Biology In Clinical Oncology WorkshopNational Cancer Institute2008–2011
Functional Analysis Of The Von Hippel-Lindau ProteinNational Cancer Institute2006–2010
A Luciferase Fusion Protein Library To Identify &Monitor Ubiquitylation TargetsNational Cancer Institute2007–2008
Signal Transduction By The Retinoblastoma ProteinNational Cancer Institute1998–2008
2006 Cancer Model MechanismsNational Cancer Institute2006
Real-Time Imaging Of Hypoxia Based On VHL ActivityNational Cancer Institute2005–2006
Using Synthetic Lethality To Select Cancer Drug TargetsNational Cancer Institute2004–2005
Functional Analysis Of The Von Hippel Lindau ProteinNational Cancer Institute2001–2005
Real-Time Imaging Of Hypoxia Based On VHL ActivityNational Cancer Institute2004
Conference On Cell Cycle 2001National Cancer Institute2001
Functional Analysis Of The Von Hippel/Lindau ProteinNational Cancer Institute1996–2000
Retinoblastoma Susceptibility Gene--Functional AnalysisNational Cancer Institute1990–1994
Retinoblastoma Susceptibility Gene: Functional AnalysisNational Cancer Institute1990